Does the media prefer EPRX or ANAB?

In the previous week, AnaptysBio had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Eupraxia Pharmaceuticals. AnaptysBio's average media sentiment score of 0.45 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EPRX or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Maze Therapeutics N/A -36.62% -31.78%

Does the media favor EPRX or MAZE?

In the previous week, Maze Therapeutics had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Maze Therapeutics and 1 mentions for Eupraxia Pharmaceuticals. Maze Therapeutics' average media sentiment score of 0.84 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or EPRX?

In the previous week, Vir Biotechnology had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Vir Biotechnology and 1 mentions for Eupraxia Pharmaceuticals. Vir Biotechnology's average media sentiment score of 0.61 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, TRLV or EPRX?

Trulieve Cannabis has higher revenue and earnings than Eupraxia Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.17B 1.41 N/A N/A N/A Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A

Is TRLV or EPRX more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Does the media prefer TRLV or EPRX?

In the previous week, Trulieve Cannabis had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Trulieve Cannabis and 1 mentions for Eupraxia Pharmaceuticals. Trulieve Cannabis' average media sentiment score of 0.33 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HROW or EPRX?

In the previous week, Harrow had 8 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 9 mentions for Harrow and 1 mentions for Eupraxia Pharmaceuticals. Harrow's average media sentiment score of 0.52 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eupraxia Pharmaceuticals (EPRX) Competitors

$6.30 -0.12 (-1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$6.73 +0.43 (+6.83%)

As of 07:50 PM Eastern

Compare

EPRX vs. ANAB, MAZE, VIR, TRLV, and HROW

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? MarketBeat compares Eupraxia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eupraxia Pharmaceuticals include AnaptysBio (ANAB), Maze Therapeutics (MAZE), Vir Biotechnology (VIR), Trulieve Cannabis (TRLV), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry.

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Eupraxia Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
AnaptysBio	-11.53%	N/A	-7.75%

In the previous week, AnaptysBio had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Eupraxia Pharmaceuticals. AnaptysBio's average media sentiment score of 0.45 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio has higher revenue and earnings than Eupraxia Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
AnaptysBio	$234.60M	6.93	-$13.23M	-$1.08	N/A

Eupraxia Pharmaceuticals currently has a consensus price target of $18.00, indicating a potential upside of 185.71%. AnaptysBio has a consensus price target of $81.82, indicating a potential upside of 49.00%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Eupraxia Pharmaceuticals and AnaptysBio tied by winning 7 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Maze Therapeutics?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Maze Therapeutics had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Maze Therapeutics and 1 mentions for Eupraxia Pharmaceuticals. Maze Therapeutics' average media sentiment score of 0.84 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Maze Therapeutics	$167.50M	9.15	-$131.12M	-$2.53	N/A

Maze Therapeutics' return on equity of -36.62% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Maze Therapeutics	N/A	-36.62%	-31.78%

Eupraxia Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, indicating a potential upside of 185.71%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 138.35%. Given Eupraxia Pharmaceuticals' higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Eupraxia Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Vir Biotechnology currently has a consensus price target of $20.88, indicating a potential upside of 123.50%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 185.71%. Given Eupraxia Pharmaceuticals' higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	22.98	-$437.99M	-$3.13	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Vir Biotechnology has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

In the previous week, Vir Biotechnology had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Vir Biotechnology and 1 mentions for Eupraxia Pharmaceuticals. Vir Biotechnology's average media sentiment score of 0.61 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Vir Biotechnology beats Eupraxia Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Trulieve Cannabis had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Trulieve Cannabis and 1 mentions for Eupraxia Pharmaceuticals. Trulieve Cannabis' average media sentiment score of 0.33 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trulieve Cannabis presently has a consensus price target of $15.00, indicating a potential upside of 74.93%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 185.71%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Trulieve Cannabis' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Trulieve Cannabis has higher revenue and earnings than Eupraxia Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.17B	1.41	N/A	N/A	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Summary

Trulieve Cannabis beats Eupraxia Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Harrow?

Harrow (NASDAQ:HROW) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

72.8% of Harrow shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Harrow had 8 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 9 mentions for Harrow and 1 mentions for Eupraxia Pharmaceuticals. Harrow's average media sentiment score of 0.52 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harrow has higher revenue and earnings than Eupraxia Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.73	-$5.14M	-$0.41	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 65.78%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, indicating a potential upside of 185.71%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Harrow has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Summary

Harrow beats Eupraxia Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$417.42M	$3.64B	$6.82B	$12.60B
Dividend Yield	N/A	2.19%	2.68%	9.52%
P/E Ratio	-6.00	11.33	22.09	21.54
Price / Sales	N/A	304.04	522.13	92.26
Price / Cash	N/A	156.74	50.43	59.93
Price / Book	4.47	8.01	10.18	6.10
Net Income	-$38.58M	$23.81M	$3.60B	$331.84M
7 Day Performance	2.27%	-1.69%	-1.95%	-1.77%
1 Month Performance	-1.41%	-1.69%	-0.77%	-3.03%
1 Year Performance	22.47%	34.50%	19.01%	14.20%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	2.1419 of 5 stars	$6.30 -1.9%	$18.00 +185.7%	+26.7%	$417.42M	N/A	N/A	29
ANAB AnaptysBio	2.5953 of 5 stars	$54.15 -3.0%	$81.82 +51.1%	+100.7%	$1.65B	$234.60M	N/A	100
MAZE Maze Therapeutics	1.9703 of 5 stars	$27.17 -7.6%	$66.00 +142.9%	+68.2%	$1.63B	$167.50M	N/A	121
VIR Vir Biotechnology	2.226 of 5 stars	$9.40 -2.2%	$20.88 +122.1%	+63.2%	$1.62B	$68.56M	N/A	580	News Coverage
TRLV Trulieve Cannabis	3.6899 of 5 stars	$8.39 -2.8%	N/A	N/A	$1.61B	$1.17B	N/A	9,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. ANAB, MAZE, VIR, TRLV, and HROW

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Summary

How does Eupraxia Pharmaceuticals compare to Maze Therapeutics?

Summary

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Summary

How does Eupraxia Pharmaceuticals compare to Trulieve Cannabis?

Summary

How does Eupraxia Pharmaceuticals compare to Harrow?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. ANAB, MAZE, VIR, TRLV, and HROW

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Which has more volatility and risk, EPRX or ANAB?

Is EPRX or ANAB more profitable?

Does the media prefer EPRX or ANAB?

Which has better valuation & earnings, EPRX or ANAB?

Do analysts rate EPRX or ANAB?

Summary

How does Eupraxia Pharmaceuticals compare to Maze Therapeutics?

Does the media favor EPRX or MAZE?

Which has stronger earnings & valuation, EPRX or MAZE?

Is EPRX or MAZE more profitable?

Which has more risk and volatility, EPRX or MAZE?

Do analysts prefer EPRX or MAZE?

Summary

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Do analysts recommend VIR or EPRX?

Which has better earnings and valuation, VIR or EPRX?

Which has more risk & volatility, VIR or EPRX?

Is VIR or EPRX more profitable?

Does the media prefer VIR or EPRX?

Do insiders and institutionals have more ownership in VIR or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Trulieve Cannabis?

Does the media prefer TRLV or EPRX?

Do analysts recommend TRLV or EPRX?

Is TRLV or EPRX more profitable?

Which has higher valuation & earnings, TRLV or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Harrow?

Do insiders and institutionals hold more shares of HROW or EPRX?

Does the media refer more to HROW or EPRX?

Which has higher earnings & valuation, HROW or EPRX?

Do analysts recommend HROW or EPRX?

Is HROW or EPRX more profitable?

Which has more volatility & risk, HROW or EPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools